Takeda acquires PvP Biologics following coeliac disease drug trial
A statement by the Takeda reveals the company has acquired PvP as part of a development and option agreement for the drug TAK-062.
List view / Grid view
News
NICE does not recommend polatuzumab vedotin to treat lymphoma
NICE has formed a negative opinion for Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine to treat diffuse large B-cell lymphoma.
Biocatalysis could be the key to shaping macrocycles
Researchers have shown that the CALB lipase enzyme can be used to produce macrocycles of a specified shape using biocatalysis.
FDA and EMA accept licence applications for multiple sclerosis treatment
The FDA and EMA have accepted licence applications for ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS).
Coronavirus update: clinical trials and antibody manufacture
The US NIH has initiated a clinical trial for remdesivir and two pharmaceutical companies will work together to manufacture antibody treatments to tackle the coronavirus.
Novartis launches review of Beovu after safety concerns, says report
An external review of the medicine Beovu has been announced by Novartis, which produces the drug, according to a new report.
Discovery could make Suzuki-Miyaura reactions cheaper and easier
An innovation in drug production methodology could enable manufacturers to use protected boronic acid in reactions, reducing the number of steps required.
Oil and hydrogel mix effective for precise dosing of medicine
Researchers have developed a new mixture of oil and hydrogel that releases drugs in a controlled fashion, preventing overdosing.
Dry eye syndrome therapies in pipeline show promise, says report
A report has revealed that the products in the pipeline to treat dry eye syndrome are expected to expand the number of options available for patients.
FDA accepts Zejula sNDA application as a maintenance treatment for ovarian cancer
The developers of Zejula (niraparib) have announced the FDA will assess the sNDA application under the Real-Time Oncology Review (RTOR) pilot programme.
FDA approves first generic of ProAir HFA inhalation aerosol
The generic of ProAir HFA (albuterol sulfate) inhalation aerosol has been approved by the FDA to advance patient access to lower-cost medicines.
FMD alert issued for diamorphine hydrochloride lyophilisate for solution by MHRA
A defect in the 2D matrix for the expiration date of diamorphine hydrochloride lyophilisate for solution has been announced by the MHRA.
COVID-19 update: therapeutic and regulatory developments
European Pharmaceutical Review rounds up the latest news surrounding COVID-19, including a vaccine moving to clinical trials and the FDA's update on Chinese import inspections.
Nanoparticle drug delivery could be the future of targeted cancer therapies
Researchers have created targeted, modifiable nanoparticles which could be combined with pharmaceuticals as a form of drug delivery to treat cancer.
FDA centres collaborate to evaluate conclusions of pharmacogenetic testing
The FDA has released a statement that two of its centres will collaborate to provide information on gene-drug interactions they believe have sufficient supporting evidence.
